TRPV4 and brain ischemia: Pharmacological blockade of TRPV4 results in reduction of brain ischemia-induced lesion volume through inhibition of matrix metalloprotease (MMP) activation, thereby providing protection against BBB disruption following transient focal cerebral ischemia (Li et al., 2013; Jie et al., 2015a, b, 2016).